Navigation Links
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
Date:1/28/2010

SAN DIEGO, Jan. 28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys®) and ribavirin (Copegus®) in refractory HCV patients.  Antiviral activity, safety and tolerability of the triple combination will be assessed after up to 48 weeks of therapy.

"There is a significant unmet medical need in HCV patients who have not responded to pegylated interferon and ribavirin.  These patients often progress to cirrhosis, a life-threatening condition.  CTS-1027 has the potential to increase the effectiveness of the combination of pegylated interferon and ribavirin in this population," said Dr. Paul J. Pockros, Head, Division of Gastroenterology and Director of the SC Liver Research Consortium and The Scripps Clinic in La Jolla, CA.

CTS-1027 is an oral, small molecule compound that inhibits the activity of key members of a class of protease enzymes, the matrix metalloproteinases or MMPs. CTS-1027's anti-inflammatory and anti-fibrotic effects have been well-established in models of acute hepatitis and liver fibrosis. In addition, CTS-1027 has been shown to reduce and/or block HCV replication in in vitro preclinical models.  

This clinical trial is an open-label design testing an optimized dose of CTS-1027 in combination with Pegasys® and Copegus® in HCV-infected patients who were prior null responders to pegylated interferon and ribavirin treatment. Dosing will last for up to 48 weeks. The Company expects approximately 60 patients to be enrolled. The clinical trial will be conducted at up to fifteen medical centers in the U.S. Additional information about the trial can be found at: www.clinicaltrials.gov (Identifier NCT01051921) or www.clinicaltrials.gov/ct2/show/NCT01051921?term=cts1027&rank=2.

"Our studies suggest that CTS-1027 treatment has the potential to amplify the effectiveness of pegylated interferon and ribavirin therapy. We believe that treating the most refractory patients will give us the best indication as to whether CTS-1027 can enhance the activity of existing therapy," said Steven J. Mento, President and CEO of Conatus. "The field is moving towards combinations of small molecules, and CTS-1027 represents a novel approach that we hope will benefit patients infected with HCV."

Conatus Pharmaceuticals Inc. is a privately-held specialty pharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease. Chronic liver disease affects millions of people worldwide and can be caused by many different conditions or "insults" to the liver including Hepatitis C and other viral infections, obesity, chronic alcohol abuse or autoimmune diseases. Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the successful sale of Idun to Pfizer. For additional information, please visit www.conatuspharma.com.

Pegasys® and Copegus® are registered trademarks of F. Hoffman-La Roche, Inc.

SOURCE Conatus Pharmaceuticals Inc.

RELATED LINKS
http://www.conatuspharma.com

'/>"/>

SOURCE Conatus Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
2. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
3. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
4. Intercept Pharmaceuticals Raises $25 Million Series B Financing
5. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
6. Amylin Pharmaceuticals to Webcast Year-End Financial Results
7. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
8. Sagent Pharmaceuticals Launches Pamidronate Disodium Injection
9. Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification
10. Barclays Wealth Recommends Increasing Exposure to Laggard Sectors Including Consumer Staples, Pharmaceuticals and Telecoms
11. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, ... Therawis bedient dringenden Bedarf ... QIAGEN N.V. (NASDAQ: QGEN ; ... Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur ... eingegangen zu sein. Ein erstes Projekt wird die ...
(Date:5/25/2016)... Florida , May 25, 2016 ... Conference & Expo earlier this month, the numbers and ... revenues continue to climb into the billions, more research ... newly released 4th Edition State of Legal Marijuana Markets ... a cannabis-focused data-analysis firm, much of the increase in ...
(Date:5/25/2016)... 2016 ReportsnReports.com adds "Chronic ... that provides an overview on therapeutic pipeline of ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Chronic Cough ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... ... Connor Sports, through its Connor Cares initiative, will continue to expand ... Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and final WNBA ... levels of the game, Connor Sports has committed to a significantly increased focus on ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cardiac arrhythmia is ... impact on long-term patient survival, reports a team of UPMC researchers in the ... in the Journal of Thoracic and Cardiovascular Surgery, provide critical information that will ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent ... for drugs, biologics, consumer health and global clinical supply services, today announced two ... support the company’s continued investment and strategic growth plans in the Asia Pacific ...
(Date:5/26/2016)... ... ... to provide hair restoration information to the widest possible audience, Dr. Parsa Mohebi is making ... app. Dr. Mohebi, the founder of Parsa Mohebi Hair Restoration, is making all of his ... says, “The positive response to the Snapchat videos we started last month has been overwhelming. ...
(Date:5/26/2016)... ... May 26, 2016 , ... Eating Recovery Center, Washington ... opening a brand new child and adolescent residential treatment center on June 1. ... even more specialized eating disorder treatment and access to life-saving care. , To ...
Breaking Medicine News(10 mins):